The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.356%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

Thu, 03rd Mar 2022 13:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Elementis PLC - London-based speciality chemicals - Swings to profit in 2021, with pretax profit of USD5.8 million, up from a loss of USD68.8 million in 2020. Strong new business momentum, targeted pricing actions and volume recovery boost revenue by 17% in the year to USD880 million from USD751 million the year before. Dividends may be reinstated in the medium term, but remain suspended. For 2022, global supply chain issues and cost inflation are a concern, but it is off to "an encouraging start".

----------

Synthomer PLC - Essex-based chemicals company - Profit before tax rockets in 2021 to GBP283.9 million from GBP20.3 million in 2020, as revenue is up 42% to GBP2.33 billion from GBP1.64 billion. Underlying pretax profit more than doubles to GBP420.1 million from GBP160.0 million. Profit is being used to make "major inorganic and organic investments" to support further growth. In 2022 so far, nitrile latex demand is "subdued" as Covid eases and inventories of medical gloves are high, while all other divisions have started 2022 well. Final dividend is 21.3 pence, over double that of 8.3p in 2020, for a total in 2021 of 30.0p, up from 11.6p the prior year.

----------

Glanbia PLC - Kilkenny, Ireland-based nutrition company - Revenue comes in ahead of expectations for 2021 at EUR4.20 billion, up 9.8% from EUR3.82 billion in 2020. Profit before tax rises 21% to EUR158.0 million from EUR131.1 million. Says performance was driven by strong global consumer demand. A final dividend of 17.53 cents is proposed, bringing the year's total to 29.28 cents, up 10% on 2020, and launches new EUR50 million share buyback. Growth in revenue is expected for 2022, and says inflationary costs will be managed with higher sales prices.

----------

Galliford Try Holdings PLC - Uxbridge, England-based construction company - Pretax profit up to GBP7.1 million in first half ended December 31 from GBP4.1 million a year before. Revenue is up 10% to GBP594 million from GBP542 million in the prior year. Order book is up to GBP3.4 billion from GBP3.3 billion a year ago. The company boosts interim dividend by 83% to 2.2 pence from 1.2p the year before. Outlook for the rest of the year is positive, with 95% of projected revenue already secured.

----------

Empiric Student Property PLC - London-based owner and operator of student accommodation - Swings to profit in 2021, with a pretax profit of GBP29.2 million from a pretax loss of GBP24.0 million. Net rental inome drops 11% year-on-year to GBP32.9 million from GBP32.9 million, with total revenue down 6% to GBP56.0 million from GBP59.4 million. Dividends resume in fourth quarter, with payment of 2.5p, and targets fully covered and progressive dividends going forward, to increase as occupancy rates normalise. For the academic year starting in 2022, Empiric expects to come in at the top of its 85% to 95% target occupancy rate.

----------

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Total revenue for 2021 is USD356.1 million up 56% year-on-year from USD228.0 million. Loss before tax of USD215.7 million widens from USD189.7 million in FY20. Momentum is continuing into 2022, and it held over USD1 billion in cash on December 31. Christian Hogg retires as chief executive officer, after 22 years with the company and 15 years as CEO. Promotes Chief Scientific Officer Weiguo Su, a 17-year company veteran, to CEO. The changes are effective from Friday.

----------

AIB Group PLC - Dublin-based bank - Swings to pretax profit of EUR629 million in 2021 from a loss of EUR931 million. Net interest income drops 4% to EUR1.79 billion from EUR1.87 billion the prior year. Gross loans were down 2% to EUR56.5 billion from EUR59.4 billion. Recommends dividend of 4.5 pence per share for the year, with no dividend having been paid in 2021. AIB expects net interest income to be "stable" in 2022.

----------

Hunting PLC - London-based energy services - In 2021, revenue drops 17% to USD521.6 million from USD626.0 million in 2020, but pretax loss from operations narrows to USD85.5 million from USD223.0 million. Second half of 2021 lifted by improved trading and recovering commodity prices, after first half hit by global reduction in activity in oil & gas. A final dividend of 4.0 cents will be paid out for the year, unchanged from 2020. As Covid-related operational issues ease in its first quarter, it predicts a "much improved" 2022.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Dec 2021 13:23

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

Read more
3 Dec 2021 09:54

Two Hutchmed drugs included on China's state approved medicines list

Two Hutchmed drugs included on China's state approved medicines list

Read more
24 Nov 2021 11:35

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Read more
1 Nov 2021 09:14

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

Read more
28 Oct 2021 21:59

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

Read more
29 Sep 2021 11:08

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

Read more
21 Sep 2021 10:51

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

Read more
20 Sep 2021 09:09

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Read more
13 Sep 2021 10:22

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

Read more
8 Sep 2021 13:49

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

Read more
6 Sep 2021 09:37

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

Read more
26 Aug 2021 10:38

Hutchmed launches trial into drug combination to treat breast cancer

Hutchmed launches trial into drug combination to treat breast cancer

Read more
9 Aug 2021 12:35

Hutchmed strikes collaboration deal with Epizyme

(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.

Read more
9 Aug 2021 10:06

Hutchmed to partner with Epizyme on tumour-targetting treatment

Hutchmed to partner with Epizyme on tumour-targetting treatment

Read more
28 Jul 2021 14:51

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.